title: Effects of cyclooxygenase-2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer.
abstract: The objective of the present study was to determine the influence of cyclooxygenase-2 (COX-2) inhibition by Celecoxib (CLX) in humans with distal colorectal adenocarcinoma (CRC) on serum and tumor levels of progastrin and gastrin and serum levels of proinflammatory cytokines (IL-8, TNF-alpha). In addition, the effects of this CLX treatment on tumor and adjacent mucosa expression of gastrin, its receptors (CCK2), and COX-1 and COX-2, as well as protein expression of the active form of nuclear factor kappa B (NFkappa B) and the apoptotic-related proteins Bcl-2 and survivin, have been examined. Ten distal CRC patients were examined twice, once before and then after 14-day treatment with CLX (200 mg bid). Large biopsy samples were taken from the tumor and intact mucosa 10 cm above the tumor. For comparison, 20 age- and sex-matched healthy controls were enrolled and treated with CLX as CRC patients. Serum levels of IL-8 and TNF-alpha were measured by enzyme-linked immunosorbent assay, and serum levels of amidated gastrins and progastrin, by specific radioimmunoassay. The gene or protein expressions of progastrin, gastrin, CCK2, COX-1, COX-2, Bcl-2, and survivin as well as NFkappa B were determined by RT-PCR or Western blot in biopsy samples of tumor and intact mucosa of CRC patients. Serum IL-8 and TNF-alpha values were severalfold higher in CRC patients than in controls. The increase in serum proinflammatory cytokines was accompanied by increased expression of the active form of NFkappa B. Serum progastrin levels were also found to be significantly higher in CRC than in controls. Treatment of CRC with CLX resulted in a significant decrease in serum levels of progastrin and this was accompanied by an increment in tumor expression of COX-2 with a concomitant reduction in gastrin, Bcl-2, survivin, and NFkappa B expression. We conclude that (1) distal CRC patients show significantly higher serum progastrin levels than matched healthy controls, confirming that this hormone may be implicated in rectal carcinogenesis; (2) CRC patients exhibit significantly higher serum levels of IL-8 and TNF-alpha than healthy controls, probably reflecting more widespread inflammatory reaction in the colonic mucosa in CRC; (3) gastrin, COX-2, Bcl-2, survivin, and NFkappa B were overexpressed in CRC tumor compared to intact mucosa, but treatment with CLX significantly reduced serum levels of progastrin and IL-8 and TNF-alpha, which could mediate the up-regulation of COX-2 in CRC; and (4) CLX also enhanced expression of COX-2, while inhibiting the expression of gastrin, Bcl-2, survivin, and NFkappa B, suggesting that COX-2 inhibition might be useful in chemoprevention against CRC, possibly due to suppression of the antiapoptotic proteins and reduction in progastrin-induced and NFkappa B-promoted tumor growth.
authors.affiliation: Department of Medicine, University Erlangen-Nuremberg, Erlangen, Germany. pkonturek@web.de
authors.forename: Peter C
authors.initials: PC
authors.lastname: Konturek
authors.forename: Kazimierz
authors.initials: K
authors.lastname: Rembiasz
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Burnat
authors.forename: Stanisław J
authors.initials: SJ
authors.lastname: Konturek
authors.forename: Marcin
authors.initials: M
authors.lastname: Tusinela
authors.forename: Władysław
authors.initials: W
authors.lastname: Bielanski
authors.forename: Jens
authors.initials: J
authors.lastname: Rehfeld
authors.forename: Danuta
authors.initials: D
authors.lastname: Karcz
authors.forename: Eckhart
authors.initials: E
authors.lastname: Hahn
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D000368:Aged; D051017:Apoptosis Regulatory Proteins / Q000032:analysis / Q000378:metabolism*; D001483:Base Sequence; D014408:Biomarkers, Tumor / Q000378:metabolism; D001707:Biopsy, Needle; D015153:Blotting, Western; D016022:Case-Control Studies; D000068579:Celecoxib; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage*; D016207:Cytokines / Q000032:analysis / Q000378:metabolism; D005260:Female; D005755:Gastrins / Q000187:drug effects / Q000378:metabolism*; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases / Q000032:analysis / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D009367:Neoplasm Staging; D011336:Probability; D011379:Prognosis; D011720:Pyrazoles / Q000008:administration & dosage*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012680:Sensitivity and Specificity; D018709:Statistics, Nonparametric; D013449:Sulfonamides / Q000008:administration & dosage*; D015996:Survival Rate
chemical_list: D051017:Apoptosis Regulatory Proteins; D014408:Biomarkers, Tumor; D052246:Cyclooxygenase 2 Inhibitors; D016207:Cytokines; D005755:Gastrins; D011720:Pyrazoles; D013449:Sulfonamides; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases; D000068579:Celecoxib